Semaglutide Research Dosage: Published Protocol Reference
Semaglutide dosage references vary by route and study context. The database lists Subcutaneous injection (diabetes): 0.25-1.0 mg, Once weekly, Subcutaneous injection (weight): 0.25-2.4 mg, Once weekly, and Subcutaneous injection (higher-dose weight): 7.2 mg maintenance, Once weekly. These are research-context references, not a universal protocol.
Direct Answer
Semaglutide remains the most broadly validated single-receptor GLP-1 medicine. Tirzepatide produces greater average weight loss in direct comparison, while semaglutide has mature cardiovascular outcomes evidence plus approved oral, kidney, and MASH uses across its product family.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Weight Loss & Metabolic
- Evidence context
- Evidence-backed obesity, type 2 diabetes, cardiovascular, kidney, and MASH indications
Research Dosage References
- <strong>Subcutaneous injection (diabetes)</strong> - 0.25-1.0 mg - Once weekly - Start at 0.25mg for 4 weeks, escalate to 0.5mg, then 1.0mg (Ozempic).
- <strong>Subcutaneous injection (weight)</strong> - 0.25-2.4 mg - Once weekly - Gradual escalation over 16-20 weeks to target dose of 2.4mg (Wegovy).
- <strong>Subcutaneous injection (higher-dose weight)</strong> - 7.2 mg maintenance - Once weekly - Wegovy HD was FDA-approved on March 19, 2026 for adults with obesity; titration follows the approved label.
- <strong>Oral (type 2 diabetes)</strong> - 3-14 mg - Once daily - Rybelsus dosing reference. Administration requirements differ by tablet formulation and should follow the current label.
- <strong>Oral (weight management)</strong> - 1.5-25 mg - Once daily - Wegovy tablets were FDA-approved in December 2025. The label uses staged escalation to the 25 mg maintenance dose.
Half-Life
~7 days (allowing once-weekly dosing).
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Semaglutide, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Boxed warning: thyroid C-cell tumors in rodents
- Contraindicated with personal/family history of medullary thyroid carcinoma
- Risk of pancreatitis
- May worsen diabetic retinopathy
- Not for use with insulin or other GLP-1 agonists
- Gallbladder events reported
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Weight Loss (Level A), Blood Sugar Control (Level A), Cardiovascular Protection (Level A), and MASH (Level A) |
| Primary citation count | 6 |
| Last reviewed | 2026-08-27 |
Quick Answers
What dosage of Semaglutide is used in research?
Semaglutide dosage references vary by route and study context. The database lists Subcutaneous injection (diabetes): 0.25-1.0 mg, Once weekly, Subcutaneous injection (weight): 0.25-2.4 mg, Once weekly, and Subcutaneous injection (higher-dose weight): 7.2 mg maintenance, Once weekly. These are research-context references, not a universal protocol.
What is the evidence level for Semaglutide?
Semaglutide is rated Level A. Its current research status is FDA Approved.
What is Semaglutide best known for?
Evidence-backed obesity, type 2 diabetes, cardiovascular, kidney, and MASH indications.
Where can I read the full Semaglutide evidence review?
The full evidence review is available at https://examinepeptides.com/library/semaglutide.
Related Guides
How to Cite This Page
ExaminePeptides. "Semaglutide Research Dosage: Published Protocol Reference." Last reviewed 2026-08-27. https://examinepeptides.com/answers/semaglutide-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.